BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15237387)

  • 21. Further SAR study on 11-O-substituted aporphine analogues: identification of highly potent dopamine D3 receptor ligands.
    Ye N; Wu Q; Zhu L; Zheng L; Gao B; Zhen X; Zhang A
    Bioorg Med Chem; 2011 Mar; 19(6):1999-2008. PubMed ID: 21334902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of 3-aryl-1-[(4-phenyl-1-piperazinyl)butyl]indazole derivatives and their affinity to 5-HT1A serotonin and dopamine D1 receptors.
    Andronati S; Sava V; Makan S; Kolodeev G
    Pharmazie; 1999 Feb; 54(2):99-101. PubMed ID: 10084155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New 5-hydroxytryptamine(1A) receptor ligands containing a norbornene nucleus: synthesis and in vitro pharmacological evaluation.
    Fiorino F; Perissutti E; Severino B; Santagada V; Cirillo D; Terracciano S; Massarelli P; Bruni G; Collavoli E; Renner C; Caliendo G
    J Med Chem; 2005 Aug; 48(17):5495-503. PubMed ID: 16107148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological evaluation of halogenated and non-halogenated arylpiperazin-1-yl-ethyl-benzimidazoles as D(2) and 5-HT(2A) receptor ligands.
    Tomić M; Vasković D; Tovilović G; Andrić D; Penjišević J; Kostić-Rajačić S
    Arch Pharm (Weinheim); 2011 May; 344(5):287-91. PubMed ID: 21509803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine/serotonin receptor ligands. 10: SAR Studies on azecine-type dopamine receptor ligands by functional screening at human cloned D1, D2L, and D5 receptors with a microplate reader based calcium assay lead to a novel potent D1/D5 selective antagonist.
    Hoefgen B; Decker M; Mohr P; Schramm AM; Rostom SA; El-Subbagh H; Schweikert PM; Rudolf DR; Kassack MU; Lehmann J
    J Med Chem; 2006 Jan; 49(2):760-9. PubMed ID: 16420061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1-Aryl-4-(4-succinimidobutyl)piperazines and their conformationally constrained analogues: synthesis, binding to serotonin (5-HT1A, 5-HT2A, 5-HT7), alpha1-adrenergic, and dopaminergic D2 receptors, and in vivo 5-HT1A functional characteristics.
    Bojarski AJ; Paluchowska MH; Duszyńska B; Kłodzińska A; Tatarczyńska E; Chojnacka-Wójcik E
    Bioorg Med Chem; 2005 Mar; 13(6):2293-303. PubMed ID: 15727878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning.
    Stewart AO; Cowart MD; Moreland RB; Latshaw SP; Matulenko MA; Bhatia PA; Wang X; Daanen JF; Nelson SL; Terranova MA; Namovic MT; Donnelly-Roberts DL; Miller LN; Nakane M; Sullivan JP; Brioni JD
    J Med Chem; 2004 Apr; 47(9):2348-55. PubMed ID: 15084133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine/serotonin receptor ligands. 16.(1) Expanding dibenz[d,g]azecines to 11- and 12-membered homologues. Interaction with dopamine D(1)-D(5) receptors.
    Enzensperger C; Müller FK; Schmalwasser B; Wiecha P; Traber H; Lehmann J
    J Med Chem; 2007 Sep; 50(18):4528-33. PubMed ID: 17676831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands.
    Ji M; Chen J; Ding K; Wu X; Varady J; Levant B; Wang S
    Bioorg Med Chem Lett; 2005 Mar; 15(6):1701-5. PubMed ID: 15745825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural determinants of pharmacological specificity between D(1) and D(2) dopamine receptors.
    Lan H; Durand CJ; Teeter MM; Neve KA
    Mol Pharmacol; 2006 Jan; 69(1):185-94. PubMed ID: 16236817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioisosteric approach in the design of new dopaminergic/serotonergic ligands.
    Soskić V; Joksimović J
    Curr Med Chem; 1998 Dec; 5(6):493-512. PubMed ID: 9873112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis of several substituted phenylpiperazines behaving as mixed D2/5HT1A ligands.
    Dukić S; Kostić-Rajacić S; Dragović D; Soskić V; Joksimović J
    J Pharm Pharmacol; 1997 Oct; 49(10):1036-41. PubMed ID: 9364416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of heterocyclic aromatic substituents on binding affinities at two distinct sites of somatostatin receptors. Correlation with the electrostatic potential of the substituents.
    Prasad V; Birzin ET; McVaugh CT; Van Rijn RD; Rohrer SP; Chicchi G; Underwood DJ; Thornton ER; Smith AB; Hirschmann R
    J Med Chem; 2003 May; 46(10):1858-69. PubMed ID: 12723949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands.
    Chu W; Tu Z; McElveen E; Xu J; Taylor M; Luedtke RR; Mach RH
    Bioorg Med Chem; 2005 Jan; 13(1):77-87. PubMed ID: 15582454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-affinity relationships of halogenated predicentrine and glaucine derivatives at D1 and D2 dopaminergic receptors: halogenation and D1 receptor selectivity.
    Asencio M; Hurtado-Guzmán C; López JJ; Cassels BK; Protais P; Chagraoui A
    Bioorg Med Chem; 2005 Jun; 13(11):3699-704. PubMed ID: 15862999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, and evaluation of hexahydrobenz[f]isoquinolines as a novel class of dopamine 3 receptor ligands.
    Wu X; Chen J; Ji M; Varady J; Levant B; Wang S
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5813-6. PubMed ID: 15501046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Geometrically constrained analogues of N-benzylindolylglyoxylylamides: [1, 2, 4]triazino[4, 3-a]benzimidazol-4(10H)-one derivatives as potential new ligands at the benzodiazepine receptor.
    Primofiore G; Da Settimo F; Taliani S; Marini AM; Simorini F; Novellino E; Greco G; Trincavelli L; Martini C
    Arch Pharm (Weinheim); 2003 Sep; 336(9):413-21. PubMed ID: 14528489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenylethyl-substituted pyrimido[2,1-f]purinediones and related compounds: structure-activity relationships as adenosine A(1) and A(2A) receptor ligands.
    Drabczyńska A; Müller CE; Schiedel A; Schumacher B; Karolak-Wojciechowska J; Fruziński A; Zobnina W; Yuzlenko O; Kieć-Kononowicz K
    Bioorg Med Chem; 2007 Nov; 15(22):6956-74. PubMed ID: 17827019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding.
    Ehrlich K; Götz A; Bollinger S; Tschammer N; Bettinetti L; Härterich S; Hübner H; Lanig H; Gmeiner P
    J Med Chem; 2009 Aug; 52(15):4923-35. PubMed ID: 19606869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.